GlucoTrack

GlucoTrack Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of GlucoTrack (GCTK) as of Oct 29, 2026 is 0.48. In the previous year, Net Debt to Free Cash Flow Ratio was 0.42 — a change of 12.82% (higher).

Net Debt/FCF

0.48

YoY

12.82%

Last updated:

Net Debt to Free Cash Flow Ratio of GlucoTrack is 2025 0.48 . Net Debt to Free Cash Flow Ratio of GlucoTrack was 2024 0.42 . It decreases by 12.82% higher compared to the previous year.

The GlucoTrack Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2018
-0.01 USD
Jan 1, 2019
0.01 USD
Jan 1, 2020
2.66 USD
Jan 1, 2021
1.54 USD
Jan 1, 2022
0.57 USD
Jan 1, 2023
0.66 USD
Jan 1, 2024
0.42 USD
Jan 1, 2025
0.48 USD
The GlucoTrack Net Debt/FCF history
YEARNet Debt/FCFYoY
0.48+12.82%
0.42-35.15%
0.66+15.42%
0.57-63.15%
1.54-42.14%
2.66+25,365.66%
0.01-171.96%
-0.01-33.39%
-0.02+790.34%
-0.00-102.57%
0.10-93.74%
1.52—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GlucoTrack Stock analysis

What does GlucoTrack do? GlucoTrack, Inc. makes money by selling non-invasive glucose monitoring devices and related software solutions to people with diabetes and pre-diabetes. The company's GlucoTrack device provides glucose level readings without finger sticks, targeting Type II diabetes and prediabetes users. It also develops an implantable continuous glucose monitor for Type I diabetes and insulin-dependent Type II diabetes patients. The firm offers companion applications and cloud-based solutions to deliver real-time, data-driven tools for diabetes management. Its primary customers are individuals managing diabetes through non-invasive monitoring solutions, with a focus on Type II diabetes and pre-diabetes segments. GlucoTrack, Inc. generates revenue through the commercialization of its non-invasive glucose monitor and the development of its implantable continuous glucose monitor. The company's products are designed for specific diabetes segments: Type II diabetes and prediabetes users for the GlucoTrack device, and Type I diabetes and insulin-dependent Type II diabetes patients for the implantable monitor. The firm's cloud-based platform and companion apps are integral to its service offering, providing personalized diabetes management tools. Revenue streams include device sales and software services for these targeted user groups. The company's business model centers on direct sales of its GlucoTrack device and implantable monitor to diabetes patients. It focuses on Type II diabetes and prediabetes for the non-invasive monitor, while the implantable version targets Type I diabetes and insulin-dependent Type II diabetes. The firm's cloud-based solutions and companion applications are sold as part of the overall diabetes management platform. Revenue is derived from both hardware sales and subscription-based software services for these specific patient segments. GlucoTrack is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GlucoTrack stock

Net Debt to Free Cash Flow Ratio of GlucoTrack is 0.48 in 2025.

Net Debt to Free Cash Flow Ratio of GlucoTrack changed from 0.42 to 0.48, representing a 12.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio GlucoTrack since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's GlucoTrack with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — GlucoTrack

All Key Metrics — GlucoTrack